Hozzászólva:: Egyéb itt Delhi | Posted:: |
The drug Sacituzumab govitecan-hziy is recommended by healthcare professionals to treat metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. This drug is sold under the brand name Trodelvy. Trodelvy single-dose vials are supplied in 180 mg and 200 mg to administer intravenously. The common Trodelvy side-effects are neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash and abdominal pain. The medicine Trodelvy was permanently discontinued for adverse reactions in 2% of patients. Adverse reactions leading to discontinuation were anaphylaxis, anorexia/fatigue, headache (each <1%, 1 patient for each event). Forty- five percent of patients experienced an adverse reaction leading to treatment interruption. The most common adverse reaction leading to treatment interruption was neutropenia (33%). Adverse reactions leading to dose reduction occurred in 33% of patients treated with Trodelvy 180 mg, with 24% having one dose reduction and 9% with two dose reductions. The most common adverse reaction leading to dose reductions was neutropenia/febrile neutropenia.